Newly patented technology aims to cut diagnostic time and variability while enabling scalable, secure sleep analysis in both clinical and home environments.
The United States Patent and Trademark Office has granted a patent to Neurobit, marketer of a suite of artificial intelligence (AI)-enabled sleep analysis solutions, to automate the detection and analysis of sleep disorders.
Designed for both clinical and at-home settings, the patented method significantly reduces diagnostic time and variability, according to the company. Its modular framework is designed to be adaptable for diverse applications, including neurological and cardiac health.
“This patent marks a transformative milestone in our mission to integrate AI into healthcare,” says Kishan, CEO of Neurobit Inc, in a release. “By deploying our system through Neurobit PSG, we are equipping hospitals and clinics with a tool that delivers faster, more accurate diagnostics, ultimately enhancing patient outcomes and driving the evolution of precision medicine.”
According to Neurobit, innovations of the patented system include:
- AI-Driven Diagnostic Precision: Automates the diagnostic process to minimize human error and variability.
- Enhanced Efficiency: Significantly reduces diagnostic time, streamlining clinical workflows.
- Scalability Across Settings: Versatile design applicable in hospitals, clinics, and home environments.
- Robust Security & Interoperability: Protects patient data with advanced encryption and integrates seamlessly with existing healthcare systems.
- Licensing Through Neurobit PSG: Available for licensing via Neurobit PSG.
